Digital Therapeutics for MCI and Alzheimer’s disease: A Regulatory Perspective (The Journal of Prevention of Alzheimer’s Disease):
–This article is adapted from a comprehensive conversation between Dr. Murali Doraiswamy and Dr. Jeffrey Shuren at the 2021 Clinical Trials on Alzheimer’s Disease (CTAD) conference in Boston. Dr. Shuren is a behavioral neurologist who has held a variety of leadership roles at the FDA and CMS, including as Director of the Center for Devices and Radiological Health (CDRH).
MD: The CDRH has a flagship Digital Health Center of Excellence. Can you tell us about it? And can you share your advice for how the Alzheimer’s field can help spur digital innovation? [Read more…] about A conversation at the frontier of digital health innovation, FDA regulations, and cognitive health